article thumbnail

US opioid activists argue against Sackler family immunity in Purdue Pharma deal

The Guardian - Pharmaceutical Industry

Under a court reorganization plan, Sackler family members who controlled the Oxycontin maker were granted immunity and did not have to declare personal bankruptcy in exchange for a $6bn settlement, paid out over 10 years, to a fund created to offset costs created by the opioid dependency crisis that has cost hundreds of thousands of lives.

article thumbnail

How long should immune checkpoint inhibitor therapy be used in non-small cell lung cancer?

Hospital Pharmacy Europe

Immune checkpoint inhibitors have transformed the management of non-small cell lung cancer, but how long should treatment be continued for optimal survival? It has long been recognised that a hallmark of cancer is immune evasion and that the immune system is held back by inhibitory immune checkpoint receptors and ligands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Judge rejects Purdue opioid settlement over Sackler family immunity

pharmaphorum

The Sacklers said earlier they would exit the settlement deal if they were not granted immunity, and the judge in the bankruptcy court that accepted the deal – Robert Drain – said he did not want to jeopardise what was on offer by seeking further changes.

article thumbnail

Purdue bankruptcy court hands immunity to Sackler family

pharmaphorum

A US federal judge has approved a bankruptcy settlement for Purdue Pharma that grants the Sackler family that owned the business immunity from any further civil lawsuits accusing them of contributing to opioid epidemic – to the consternation of campaigners.

article thumbnail

Novartis acquisition to address inflammation-driven diseases

European Pharmaceutical Review

This pathway works in the innate immune system to sense cytosolic DNA by triggering a STING-dependent inflammatory response. In September 2019, IFM Due entered into an option and collaboration agreement with Novartis, who agreed to finance IFM Due’s research and development costs for the cGAS-STING programme.

article thumbnail

Gilead to acquire MiroBio for $405 million

European Pharmaceutical Review

The deal includes MiroBio’s proprietary I-ReSToRE ( RE ceptor S election and T argeting t o R einstate immune E quilibrium) discovery platform and its entire portfolio of immune inhibitory receptor agonists. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response. . “We

article thumbnail

MHRA authorises new COVID-19 vaccine

European Pharmaceutical Review

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.